Targeted Drug Delivery System for Kidney and/or Liver Failure Patients Using Human Serum Albumin
Class
Article
Department
Biological and Irrigation Engineering
Faculty Mentor
Elizabeth Vargis
Presentation Type
Oral Presentation
Abstract
In America, roughly 10% of adults have some level of chronic kidney disease (CKD), and the same percentage suffer from liver disease. Compromised liver and/or kidney function reduces the acceptable dosage of a variety of medications that can be administered to patients. These patients still have a need for drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), antivirals, and antibiotics. The project goal was to provide a drug delivery system to accommodate these reduced dosage limits with added therapeutic benefits to address symptoms of liver or kidney failure. Localized drug delivery allows for a smaller, concentrated dose rather than inundating the patient's system with the drug of interest. Human serum albumin (HSA) is a researched candidate for drug delivery with therapeutic properties. HSA was tested as a drug delivery vehicle for localized, percutaneous drug release aided by a displacing compound and changes in temperature and ultrasound generated by an external device. Dynamic light scattering (DLS), UV/Vis spectroscopy, and optical microscopy were employed in verifying drug binding, release, and effectiveness. The optimization of the proposed drug release method, the design of the device to promote drug delivery, and the testing of the drug delivery system with in vitro tissue testing were performed to validate the designed system.
Start Date
4-9-2015 12:00 PM
Targeted Drug Delivery System for Kidney and/or Liver Failure Patients Using Human Serum Albumin
In America, roughly 10% of adults have some level of chronic kidney disease (CKD), and the same percentage suffer from liver disease. Compromised liver and/or kidney function reduces the acceptable dosage of a variety of medications that can be administered to patients. These patients still have a need for drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), antivirals, and antibiotics. The project goal was to provide a drug delivery system to accommodate these reduced dosage limits with added therapeutic benefits to address symptoms of liver or kidney failure. Localized drug delivery allows for a smaller, concentrated dose rather than inundating the patient's system with the drug of interest. Human serum albumin (HSA) is a researched candidate for drug delivery with therapeutic properties. HSA was tested as a drug delivery vehicle for localized, percutaneous drug release aided by a displacing compound and changes in temperature and ultrasound generated by an external device. Dynamic light scattering (DLS), UV/Vis spectroscopy, and optical microscopy were employed in verifying drug binding, release, and effectiveness. The optimization of the proposed drug release method, the design of the device to promote drug delivery, and the testing of the drug delivery system with in vitro tissue testing were performed to validate the designed system.